Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma

Yalei Zhao; Lingjian Zhang; Qingqing Hu; Danhua Zhu; Zhongyang Xie

doi:10.1016/j.compbiomed.2022.106348

Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma

Comput Biol Med. 2023 Jan:152:106348. doi: 10.1016/j.compbiomed.2022.106348. Epub 2022 Nov 28.

Authors

Yalei Zhao¹, Lingjian Zhang², Qingqing Hu², Danhua Zhu², Zhongyang Xie³

Affiliations

¹ Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
² State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Electronic address: zyxie@zju.edu.cn.

PMID: 36470143
DOI: 10.1016/j.compbiomed.2022.106348

Abstract

C17orf53 is a novel gene for DNA synthesis and homologous recombination. However, the exact role of C17orf53 in hepatocellular carcinoma (HCC) remains unclear. In this study, we analyzed it using a set of public datasets. UALCAN, Human Protein Atlas (HPA), Kaplan‒Meier Plotter, Tumor Immune Estimation Resource (TIMER), cBioPortal, GEPIA, GeneMANIA, and LinkedOmics were used. Functional analysis was conducted in SK-Hep-1 cells by using small interfering RNA (siRNA). C17orf53 was highly expressed and predicted unfavorable survival in HCC patients. Moreover, it showed positive correlations with the abundance of B cells, macrophages and dendritic cells. In addition, we identified 126 genes that were positively correlated with C17orf53 and its coeffector minichromosome maintenance 8 (MCM8). These genes were mainly enriched in the cell cycle, DNA replication and Fanconi anemia pathways. Knockdown of C17orf53 significantly inhibited the proliferation of SK-Hep-1 cells and decreased the expression of MCM8, cyclin D1 and proliferating cell nuclear antigen (PCNA). Overall, C17orf53 is a novel prognostic signature for HCC.

Keywords: C17orf53; Hepatocellular carcinoma; MCM8; Prognosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor
Carcinoma, Hepatocellular* / genetics
Cell Cycle
Humans
Liver Neoplasms* / genetics
Macrophages
Prognosis

Substances

Biomarkers, Tumor